126 related articles for article (PubMed ID: 38919755)
21. Prothrombin complex concentrates and andexanet for management of direct factor Xa inhibitor related bleeding: a meta-analysis.
Luo C; Chen F; Chen YH; Zhao CF; Feng CZ; Liu HX; Luo DZQ
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2637-2653. PubMed ID: 33829451
[TBL] [Abstract][Full Text] [Related]
22. A Retrospective Review of Four-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-Related Bleedings.
Hitchcock ZR; Smith SD; Le LT; Lees LR; Brandt MD
J Pharm Pract; 2023 Apr; 36(2):221-226. PubMed ID: 34231410
[TBL] [Abstract][Full Text] [Related]
23. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage.
Frontera JA; Bhatt P; Lalchan R; Yaghi S; Ahuja T; Papadopoulos J; Joset D
J Thromb Thrombolysis; 2020 Jan; 49(1):121-131. PubMed ID: 31664662
[TBL] [Abstract][Full Text] [Related]
24. Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate.
Sutton SS; Magagnoli J; Cummings TH; Dettling T; Lovelace B; Christoph MJ; Hardin JW
J Thromb Thrombolysis; 2023 Jul; 56(1):137-146. PubMed ID: 37219827
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Andexanet Alfa for Bleeding Caused by Factor Xa Inhibitors: A Systematic Review and Meta-Analysis.
Shrestha DB; Budhathoki P; Adhikari A; Shrestha S; Khati N; Mir WAY; Joshi T; Shrestha A
Cureus; 2021 Dec; 13(12):e20632. PubMed ID: 35103198
[TBL] [Abstract][Full Text] [Related]
26. Concomitant andexanet alfa and 4 F-PCC for Factor Xa inhibitor associated intracranial hemorrhage.
Orban JE; Ruckel C; Harlan S
Clin Neurol Neurosurg; 2023 Oct; 233():107908. PubMed ID: 37515854
[TBL] [Abstract][Full Text] [Related]
27. In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra.
Brinkman HJM; Zuurveld M; Meijers JCM
Res Pract Thromb Haemost; 2022 Jul; 6(5):e12775. PubMed ID: 35928523
[TBL] [Abstract][Full Text] [Related]
28. Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage.
Troyer C; Nguyen W; Xie A; Wimer D
J Thromb Thrombolysis; 2023 Jan; 55(1):149-155. PubMed ID: 36355324
[TBL] [Abstract][Full Text] [Related]
29. Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis.
Nederpelt CJ; Naar L; Krijnen P; le Cessie S; Kaafarani HMA; Huisman MV; Velmahos GC; Schipper IB
Crit Care Med; 2021 Oct; 49(10):e1025-e1036. PubMed ID: 33967205
[TBL] [Abstract][Full Text] [Related]
30. Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo.
Rayatdoost F; Deventer K; Rossaint R; Schöchl H; Grottke O
Br J Anaesth; 2024 Feb; 132(2):251-259. PubMed ID: 38030550
[TBL] [Abstract][Full Text] [Related]
31. Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors.
Tao J; Bukanova EN; Akhtar S
J Intensive Care; 2018; 6():34. PubMed ID: 29942519
[TBL] [Abstract][Full Text] [Related]
32. Reversal of factor Xa inhibitors associated intracranial haemorrhage at a tertiary medical centre.
Milioglou L; Liao K; Traeger J; McKenzie C; Burrelli C; Khunayfir AKB; Makii J; Hoffer A
Blood Coagul Fibrinolysis; 2022 Jul; 33(5):261-265. PubMed ID: 35153278
[TBL] [Abstract][Full Text] [Related]
33. Deterioration free discharge comparison of andexanet-alfa and prothrombin complex concentrates (PCC) for reversal of factor Xa inhibitor associated bleeds.
Keinath JJ; Lekura J; Hauser CD; Bajwa MK; Bloome ME; Kalus JS; Jones MC
J Thromb Thrombolysis; 2023 Aug; 56(2):315-322. PubMed ID: 37289371
[TBL] [Abstract][Full Text] [Related]
34. An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage.
Giovino A; Shomo E; Busey KV; Case D; Brockhurst A; Concha M
Clin Neurol Neurosurg; 2020 Aug; 195():106070. PubMed ID: 32679541
[TBL] [Abstract][Full Text] [Related]
35. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.
Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K
J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220
[TBL] [Abstract][Full Text] [Related]
36. Four-factor prothrombin complex concentrate administration after expanding intracranial hemorrhage status post administration of andexanet alfa.
Blackburn M
Am J Emerg Med; 2022 Dec; 62():144.e1-144.e3. PubMed ID: 36038405
[TBL] [Abstract][Full Text] [Related]
37. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
Maragkos GA; Nelton EB; Richter S; Stippler M
World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488
[TBL] [Abstract][Full Text] [Related]
38. Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding.
Cohen AT; Lewis M; Connor A; Connolly SJ; Yue P; Curnutte J; Alikhan R; MacCallum P; Tan J; Green L
J Am Coll Emerg Physicians Open; 2022 Apr; 3(2):e12655. PubMed ID: 35280921
[TBL] [Abstract][Full Text] [Related]
39. Real-world utilization of andexanet alfa.
Brown CS; Scott RA; Sridharan M; Rabinstein AA
Am J Emerg Med; 2020 Apr; 38(4):810-814. PubMed ID: 31870672
[TBL] [Abstract][Full Text] [Related]
40. Administration of andexanet alfa for traumatic intracranial hemorrhage in the setting of massive apixaban overdose: A case report.
Jenniches D; Kerns AF; DelBianco J; Stripp MP; Philp AS
Am J Health Syst Pharm; 2023 Nov; 80(23):1722-1728. PubMed ID: 37688311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
